• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Study Published in the Journal of the American Medical Association Shows Major Health Benefits With Obesity Surgery

Posted on: Tuesday, 19 October 2004, 12:00 CDT

INAMED Corporation (Nasdaq:IMDC):

-- Meta-analysis Shows Link Between Weight Loss Surgery and Significant Resolution of Obesity-Related Diseases Examined

-- Major Obesity Diseases Reviewed Show Improvement

-- 77% of Diabetes Patients Had Complete Resolution of Disease

INAMED Corporation, (Nasdaq:IMDC) manufacturer of the LAP-BAND(R) System, the only FDA-approved gastric banding option, learned today that the Journal of the American Medical Association (JAMA) has published a systematic review and meta-analysis of 136 studies with a total of 22,094 morbidly obese patients on the impact of bariatric surgery (including gastric banding) on weight loss, operative mortality and four major obesity comorbidities.

The study found that the typical bariatric patients lost more than 60% of their excess weight; associated comorbid conditions, such as diabetes, were resolved in 77% of the patients who had that disease. In addition, patients with high blood pressure (62%), hyperlipidemia (70% -- high cholesterol and high triglycerides) and sleep apnea (83% -- sleep obstructed breathing) experienced complete resolution or improvement of their conditions.

"This review and analysis in JAMA builds on the growing body of evidence that bariatric surgery saves lives, resolves diseases and, by extension, saves health care dollars," says Nick Teti, Chairman, President and Chief Executive Officer of INAMED. "Bariatric surgery works; it is time to care for patients, save lives and provide adequate reimbursement to ensure that these surgical options are available to every morbidly obese patient."

The October 13, 2004 JAMA article noted the dramatic increase in obesity in the past decade and that the morbidly obese do not respond well to diet and drug therapy, but do respond well to bariatric surgery. Its overall conclusion was that effective weight loss and improvement in comorbid disease was achieved in a substantial majority of morbidly obese patients after bariatric surgery.

A copy of the paper can be found at: http://jama.ama-assn.org/cgi/reprint/292/14/1724.pdf

INAMED Corporation, a global healthcare company with over 25 years of experience developing, manufacturing and marketing innovative, high-quality, science-based products, developed the LAP-BAND System. Other current products include breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products for facial rejuvenation; and a minimally-invasive device for obesity intervention.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, express and implied statements regarding INAMED's LAP-BAND(R) System product platform. INAMED is providing this information as of October 18, 2004 and expressly disclaims any duty to update information contained in this press release.

These forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied here. Readers are referred to the documents filed by INAMED Corporation with the Securities and Exchange Commission, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements, including but not limited to: exposure to product liability and intellectual property claims; exposure to liabilities that may not be adequately covered by insurance or for which there is no insurance; potential negative publicity concerning product safety; changes in the economy and consumer spending; competition from existing and/or new products; failure or delay of clinical trials; uncertainty in receiving timely regulatory approval or market acceptance for new products; dependence on a single supplier for INAMED's silicone raw materials; failure to protect INAMED's intellectual property; and adverse changes in the regulatory or legislative environment (both in the U.S. and internationally) affecting our business. The information contained in this press release is a statement of INAMED's present intention, belief or expectation and is based upon, among other things, the existing regulatory environment, industry conditions, market conditions and prices, the economy in general and INAMED's assumptions. INAMED may change its intention, belief or expectation, at any time and without notice, based upon any changes in such factors, in INAMED's assumptions or otherwise. INAMED undertakes no obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

By including any information in this press release, INAMED does not necessarily acknowledge that disclosure of such information is required by applicable law or that the information is material.

Source: Business Wire

More News in this Category